- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05888506
Ketone Ester Supplementation and Nocturnal Blood Pressure
The Effects of Ketone Ester Supplementation on Nocturnal Blood Pressure in Middle-Aged and Older Adults
Study Overview
Status
Intervention / Treatment
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death globally, killing one American approximately every 40 seconds. Among known risk factors, hypertension, or high blood pressure (BP), is the most important risk factor for the development of CVD. While sleeping, a healthy adult will experience a blood pressure dip of about 10% compared to resting values while awake. However, advancing age is associated with reduced blood pressure dipping, which is linked with an increased risk for CVD. Moreover, attenuated blood pressure dipping results in elevated nighttime blood pressure, which is in general a better predictor of cardiovascular outcomes than daytime blood pressure.
The autonomic nervous system plays a key role in blood pressure regulation and autonomic dysregulation is implicated in the pathophysiology of hypertension. Advancing age is associated with structural and function changes in the autonomic nervous system, which likely contribute, at least in part, to the marked elevation in the prevalence of hypertension and CVD that is observed in older adults. Heart rate variability (HRV) is an inexpensive and accessible index of autonomic function that is shown to decline rapidly form the second to fifth decades of life. Thus, strategies to improve nocturnal HRV may help to restore a more healthy nighttime blood pressure phenotype. However, this remains to be proven. Moreover, the link between aging, nocturnal HRV, and nighttime blood pressure is unclear.
Hypertension costs the United States between $131 and $198 billion dollars each year. Therefore, there exists a critical need to find ways to mitigate these negative health effects and costs to both the American public, and populations across the globe. Interestingly, there is a small but emerging body of evidence suggesting that ketone bodies may positively impact endothelial function and vascular health. In rodents, ketone supplementation prevents high-salt induced increase in blood pressure, blood vessel dysfunction, and kidney injury. However, there is a lack of data regarding whether ketone supplementation may provide similar cardiovascular health benefits in humans. Thus, in this first-of-kind placebo-controlled, randomized crossover design acute ketone supplementation study the investigations will evaluate the hypothesis that acute ketone supplementation will improve nocturnal blood pressure and HRV in middle-aged and older adults.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gregory J Grosicki, PhD
- Phone Number: 703-303-7812
- Email: ggrosicki@georgiasouthern.edu
Study Contact Backup
- Name: James E Brown, BS
- Phone Number: 843-259-5181
- Email: jb63845@georgiasouthern.edu
Study Locations
-
-
Georgia
-
Savannah, Georgia, United States, 31419
- Biodynamics and Human Performance Center
-
Contact:
- Gregory J Grosicki, PhD
- Phone Number: 703-303-7812
- Email: ggrosicki@georgiasouthern.edu
-
Principal Investigator:
- Gregory J Grosicki, PhD
-
Sub-Investigator:
- Andrew A Flatt, PhD
-
Sub-Investigator:
- James E Brown, BS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Greater than or equal to 50 years of age
- Body mass index (BMI) below 40 kg/m^2
- No alterations to use of prescription medication within the past 6 months
Exclusion Criteria:
- Alterations to use of prescription medication within the past 6 months
- Allergy to any of the ingredients in the ketone beverage
- Communication barriers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketone Ester
Participants will consume the supplement prior to bedtime.
Nocturnal blood pressure, heart rate, and sleep characteristics will be assessed
|
Participants will consume the ketone ester beverage produced by KetoneAid prior to bedtime.
Participants will consume 60 mL (30 grams ketones) of the ketone beverage.
|
Placebo Comparator: Placebo Supplement
Participants will consume the supplement prior to bedtime.
Nocturnal blood pressure, heart rate, and sleep characteristics will be assessed
|
Participants will consume the placebo supplement prior to bedtime.
The placebo supplement will be a ketone ester-free, taste and viscosity-matched, beverage produced by KetoneAid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nocturnal blood pressure dipping
Time Frame: Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
The investigations will use ambulatory blood pressure monitoring to characterize night-to-day blood pressure ratio
|
Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nighttime blood pressure
Time Frame: Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
The investigations will use ambulatory blood pressure monitoring to characterize nighttime blood pressure (mmHg)
|
Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Nighttime heart rate variability
Time Frame: Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
The investigators will use a single-lead electrocardiograph to characterize nocturnal heart rate variability (ms)
|
Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Objective sleep duration
Time Frame: Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Actigraph accelerometers will be used to quantify sleep duration
|
Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Objective sleep efficiency
Time Frame: Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Actigraph accelerometers will be used to quantify % of time in bed actually spent sleeping to calculate sleep efficiency
|
Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Subjective sleep quality
Time Frame: Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
A single-item visual analogue sleep scale will be used to quantify subjective sleep quality (i.e., 0 to 100, with a higher score indicating better sleep)
|
Night one of supplement ingestion (i.e., from time asleep to time awake for one night per condition)
|
Subjective sleep quality
Time Frame: Pre-intervention
|
The investigators will use the Pittsburgh Sleep Quality Index (PSQI) to assess perceived sleep quality reflective of the one month period leading into the study.
PSQI scores range from 0-21, with a higher score indicting worse sleep.
|
Pre-intervention
|
Pulse wave analysis
Time Frame: Pre-intervention
|
The investigators will use the SphygmoCor XCEL system to assess pulse wave analysis (PWA) The sampling site is the brachial artery (upper alarm instrumented with a cuff for oscillometric sphygmomanometer).
|
Pre-intervention
|
Pulse wave velocity
Time Frame: Pre-intervention
|
The investigators will use the SphygmoCor XCEL system to assess pulse wave velocity (PWV).
A high-fidelity strain-gauge transducer is used to obtain the pressure waveform at the carotid pulse.
Distances from the carotid artery sampling site to the femoral artery (upper leg instrumented with a thigh cuff for oscillometric sphygmomanometry), and from the carotid artery to the suprasternal notch will be recorded.
PWV will be expressed as m/s.
|
Pre-intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gregory J Grosicki, PhD, Georgia Southern University
Publications and helpful links
General Publications
- Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008 Jan;51(1):55-61. doi: 10.1161/HYPERTENSIONAHA.107.100727. Epub 2007 Nov 26.
- Chakraborty S, Galla S, Cheng X, Yeo JY, Mell B, Singh V, Yeoh B, Saha P, Mathew AV, Vijay-Kumar M, Joe B. Salt-Responsive Metabolite, beta-Hydroxybutyrate, Attenuates Hypertension. Cell Rep. 2018 Oct 16;25(3):677-689.e4. doi: 10.1016/j.celrep.2018.09.058.
- Valensi P. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications. Cardiovasc Diabetol. 2021 Aug 19;20(1):170. doi: 10.1186/s12933-021-01356-w.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H23223
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Ketone Ester
-
Insel Gruppe AG, University Hospital BernWithdrawn
-
BHB Therapeutics, Ireland LTDMérieux NutriSciences BiofortisCompleted
-
University of Alabama at BirminghamWithdrawnObesity | Overweight | Overweight and Obesity | Triglycerides High
-
Buck Institute for Research on AgingBiofortis Mérieux NutriSciencesActive, not recruiting
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
University of AarhusAarhus University HospitalNot yet recruiting
-
Sohag UniversityRecruiting
-
KU LeuvenCompletedHypoxia | Sleep | KetosisBelgium
-
KU LeuvenCompleted
-
United States Army Research Institute of Environmental...Active, not recruitingKetosis | Glucose MetabolismUnited States